3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia: Biological and clinical features

Nicoletta Testoni, Gabriela Borsaru, Giovanni Martinelli, Cristina Carboni, Deborah Ruggeri, Emanuela Ottaviani, Susanna Pelliconi, Paolo Ricci, Rocco Pastano, Giuseppe Visani, Alfonso Zaccaria, Sante Tura

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Background and Objective. Acute myeloblastic leukemia (AML) with features of myelodysplastic syndrome (MDS) and abnormalities of megakaryocytopolesis is often characterized by cytogenetic aberrations of the 3q21 and 3q26 bands involving inv(3)(q21q26) and (3;3)(q21;q26). These aberrations have been described in all FAB subtypes with the exception of M3, and in MDS and in megakaryoblastic crisis of chronic myeloid leukemia. We reviewed the biological and clinical features of 10 cases of AML with inv(3)(q21q26) and t(3;3)(q21;q26). Design and Methods. Four hundred and sixteen patients with AML were studied in our Institute by cytogenetic analysis and 10 (2.4%) showed inv(3)(q21q26) (7 patients) or t(3;3)(q21;q26) (3 patients): 7 males, 3 females; median age, 43.5 yrs. we also used RT-PCR to Investigate the pattern of expression of the EVI-1 gene in 5 patients. Results. Additional chromosomal changes were demonstrated in 6 patients. In 5/10 cases a preceding MDS had been observed. A possible occupational exposure was established in 2 patients (a farmer and an histologist employing organic solvents) and another patient had a therapy-related leukemia. AML subtype was M1 in 9 patients and M2 in 1. A variable excess of micromegakaryocytes was observed in all the patients. In 5 patients the platelet count was normal or Increased (median number: 172.5x109/L; range 55-440). Expression of EVI-1 gene was present in all the 5 patients studied. The clinical course and outcome was extremely poor: 9/10 patients were resistant and 1 patient showed a partial remission after induction therapy. Of the 9 patients resistant to the first line chemotherapy, 7 were also resistant to the second line chemotherapy. Three patients obtained a morphologic complete remission after third line chemotherapy (duration 1, 3 and 6 months); 2 of them were submitted to autologous bone marrow transplantation, but relapsed after 1 and 3 months. The median overall survival was 5.5 months. Interpretation and Conclusions. Our findings evidence a strong correlation between 3q21q26 chromosomal aberrations, abnormalities of megakaryocytopoiesis and lack of response to conventional chemotherapy and support the diagnostic and prognostic relevance of chromosome characterization in the classification of AML.

Original languageEnglish
Pages (from-to)690-694
Number of pages5
JournalHaematologica
Volume84
Issue number8
Publication statusPublished - Aug 1999

Fingerprint

Acute Myeloid Leukemia
Chromosome Aberrations
Myelodysplastic Syndromes
Drug Therapy
Thrombopoiesis
Remission Induction
Autologous Transplantation
Cytogenetic Analysis
Occupational Exposure
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone Marrow Transplantation
Platelet Count
Genes
Leukemia
Chromosomes

Keywords

  • 3q abnormalities
  • Acute myeloblastic leukemia
  • Cytogenetics
  • EVI-1 expression
  • Myelodysplastic syndrome

ASJC Scopus subject areas

  • Hematology

Cite this

Testoni, N., Borsaru, G., Martinelli, G., Carboni, C., Ruggeri, D., Ottaviani, E., ... Tura, S. (1999). 3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia: Biological and clinical features. Haematologica, 84(8), 690-694.

3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia : Biological and clinical features. / Testoni, Nicoletta; Borsaru, Gabriela; Martinelli, Giovanni; Carboni, Cristina; Ruggeri, Deborah; Ottaviani, Emanuela; Pelliconi, Susanna; Ricci, Paolo; Pastano, Rocco; Visani, Giuseppe; Zaccaria, Alfonso; Tura, Sante.

In: Haematologica, Vol. 84, No. 8, 08.1999, p. 690-694.

Research output: Contribution to journalArticle

Testoni, N, Borsaru, G, Martinelli, G, Carboni, C, Ruggeri, D, Ottaviani, E, Pelliconi, S, Ricci, P, Pastano, R, Visani, G, Zaccaria, A & Tura, S 1999, '3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia: Biological and clinical features', Haematologica, vol. 84, no. 8, pp. 690-694.
Testoni N, Borsaru G, Martinelli G, Carboni C, Ruggeri D, Ottaviani E et al. 3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia: Biological and clinical features. Haematologica. 1999 Aug;84(8):690-694.
Testoni, Nicoletta ; Borsaru, Gabriela ; Martinelli, Giovanni ; Carboni, Cristina ; Ruggeri, Deborah ; Ottaviani, Emanuela ; Pelliconi, Susanna ; Ricci, Paolo ; Pastano, Rocco ; Visani, Giuseppe ; Zaccaria, Alfonso ; Tura, Sante. / 3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia : Biological and clinical features. In: Haematologica. 1999 ; Vol. 84, No. 8. pp. 690-694.
@article{2e7672f2679d401b99b82fc446e5d869,
title = "3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia: Biological and clinical features",
abstract = "Background and Objective. Acute myeloblastic leukemia (AML) with features of myelodysplastic syndrome (MDS) and abnormalities of megakaryocytopolesis is often characterized by cytogenetic aberrations of the 3q21 and 3q26 bands involving inv(3)(q21q26) and (3;3)(q21;q26). These aberrations have been described in all FAB subtypes with the exception of M3, and in MDS and in megakaryoblastic crisis of chronic myeloid leukemia. We reviewed the biological and clinical features of 10 cases of AML with inv(3)(q21q26) and t(3;3)(q21;q26). Design and Methods. Four hundred and sixteen patients with AML were studied in our Institute by cytogenetic analysis and 10 (2.4{\%}) showed inv(3)(q21q26) (7 patients) or t(3;3)(q21;q26) (3 patients): 7 males, 3 females; median age, 43.5 yrs. we also used RT-PCR to Investigate the pattern of expression of the EVI-1 gene in 5 patients. Results. Additional chromosomal changes were demonstrated in 6 patients. In 5/10 cases a preceding MDS had been observed. A possible occupational exposure was established in 2 patients (a farmer and an histologist employing organic solvents) and another patient had a therapy-related leukemia. AML subtype was M1 in 9 patients and M2 in 1. A variable excess of micromegakaryocytes was observed in all the patients. In 5 patients the platelet count was normal or Increased (median number: 172.5x109/L; range 55-440). Expression of EVI-1 gene was present in all the 5 patients studied. The clinical course and outcome was extremely poor: 9/10 patients were resistant and 1 patient showed a partial remission after induction therapy. Of the 9 patients resistant to the first line chemotherapy, 7 were also resistant to the second line chemotherapy. Three patients obtained a morphologic complete remission after third line chemotherapy (duration 1, 3 and 6 months); 2 of them were submitted to autologous bone marrow transplantation, but relapsed after 1 and 3 months. The median overall survival was 5.5 months. Interpretation and Conclusions. Our findings evidence a strong correlation between 3q21q26 chromosomal aberrations, abnormalities of megakaryocytopoiesis and lack of response to conventional chemotherapy and support the diagnostic and prognostic relevance of chromosome characterization in the classification of AML.",
keywords = "3q abnormalities, Acute myeloblastic leukemia, Cytogenetics, EVI-1 expression, Myelodysplastic syndrome",
author = "Nicoletta Testoni and Gabriela Borsaru and Giovanni Martinelli and Cristina Carboni and Deborah Ruggeri and Emanuela Ottaviani and Susanna Pelliconi and Paolo Ricci and Rocco Pastano and Giuseppe Visani and Alfonso Zaccaria and Sante Tura",
year = "1999",
month = "8",
language = "English",
volume = "84",
pages = "690--694",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",
number = "8",

}

TY - JOUR

T1 - 3q21 and 3q26 cytogenetic abnormalities in acute myeloblastic leukemia

T2 - Biological and clinical features

AU - Testoni, Nicoletta

AU - Borsaru, Gabriela

AU - Martinelli, Giovanni

AU - Carboni, Cristina

AU - Ruggeri, Deborah

AU - Ottaviani, Emanuela

AU - Pelliconi, Susanna

AU - Ricci, Paolo

AU - Pastano, Rocco

AU - Visani, Giuseppe

AU - Zaccaria, Alfonso

AU - Tura, Sante

PY - 1999/8

Y1 - 1999/8

N2 - Background and Objective. Acute myeloblastic leukemia (AML) with features of myelodysplastic syndrome (MDS) and abnormalities of megakaryocytopolesis is often characterized by cytogenetic aberrations of the 3q21 and 3q26 bands involving inv(3)(q21q26) and (3;3)(q21;q26). These aberrations have been described in all FAB subtypes with the exception of M3, and in MDS and in megakaryoblastic crisis of chronic myeloid leukemia. We reviewed the biological and clinical features of 10 cases of AML with inv(3)(q21q26) and t(3;3)(q21;q26). Design and Methods. Four hundred and sixteen patients with AML were studied in our Institute by cytogenetic analysis and 10 (2.4%) showed inv(3)(q21q26) (7 patients) or t(3;3)(q21;q26) (3 patients): 7 males, 3 females; median age, 43.5 yrs. we also used RT-PCR to Investigate the pattern of expression of the EVI-1 gene in 5 patients. Results. Additional chromosomal changes were demonstrated in 6 patients. In 5/10 cases a preceding MDS had been observed. A possible occupational exposure was established in 2 patients (a farmer and an histologist employing organic solvents) and another patient had a therapy-related leukemia. AML subtype was M1 in 9 patients and M2 in 1. A variable excess of micromegakaryocytes was observed in all the patients. In 5 patients the platelet count was normal or Increased (median number: 172.5x109/L; range 55-440). Expression of EVI-1 gene was present in all the 5 patients studied. The clinical course and outcome was extremely poor: 9/10 patients were resistant and 1 patient showed a partial remission after induction therapy. Of the 9 patients resistant to the first line chemotherapy, 7 were also resistant to the second line chemotherapy. Three patients obtained a morphologic complete remission after third line chemotherapy (duration 1, 3 and 6 months); 2 of them were submitted to autologous bone marrow transplantation, but relapsed after 1 and 3 months. The median overall survival was 5.5 months. Interpretation and Conclusions. Our findings evidence a strong correlation between 3q21q26 chromosomal aberrations, abnormalities of megakaryocytopoiesis and lack of response to conventional chemotherapy and support the diagnostic and prognostic relevance of chromosome characterization in the classification of AML.

AB - Background and Objective. Acute myeloblastic leukemia (AML) with features of myelodysplastic syndrome (MDS) and abnormalities of megakaryocytopolesis is often characterized by cytogenetic aberrations of the 3q21 and 3q26 bands involving inv(3)(q21q26) and (3;3)(q21;q26). These aberrations have been described in all FAB subtypes with the exception of M3, and in MDS and in megakaryoblastic crisis of chronic myeloid leukemia. We reviewed the biological and clinical features of 10 cases of AML with inv(3)(q21q26) and t(3;3)(q21;q26). Design and Methods. Four hundred and sixteen patients with AML were studied in our Institute by cytogenetic analysis and 10 (2.4%) showed inv(3)(q21q26) (7 patients) or t(3;3)(q21;q26) (3 patients): 7 males, 3 females; median age, 43.5 yrs. we also used RT-PCR to Investigate the pattern of expression of the EVI-1 gene in 5 patients. Results. Additional chromosomal changes were demonstrated in 6 patients. In 5/10 cases a preceding MDS had been observed. A possible occupational exposure was established in 2 patients (a farmer and an histologist employing organic solvents) and another patient had a therapy-related leukemia. AML subtype was M1 in 9 patients and M2 in 1. A variable excess of micromegakaryocytes was observed in all the patients. In 5 patients the platelet count was normal or Increased (median number: 172.5x109/L; range 55-440). Expression of EVI-1 gene was present in all the 5 patients studied. The clinical course and outcome was extremely poor: 9/10 patients were resistant and 1 patient showed a partial remission after induction therapy. Of the 9 patients resistant to the first line chemotherapy, 7 were also resistant to the second line chemotherapy. Three patients obtained a morphologic complete remission after third line chemotherapy (duration 1, 3 and 6 months); 2 of them were submitted to autologous bone marrow transplantation, but relapsed after 1 and 3 months. The median overall survival was 5.5 months. Interpretation and Conclusions. Our findings evidence a strong correlation between 3q21q26 chromosomal aberrations, abnormalities of megakaryocytopoiesis and lack of response to conventional chemotherapy and support the diagnostic and prognostic relevance of chromosome characterization in the classification of AML.

KW - 3q abnormalities

KW - Acute myeloblastic leukemia

KW - Cytogenetics

KW - EVI-1 expression

KW - Myelodysplastic syndrome

UR - http://www.scopus.com/inward/record.url?scp=0032833342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032833342&partnerID=8YFLogxK

M3 - Article

C2 - 10457403

AN - SCOPUS:0032833342

VL - 84

SP - 690

EP - 694

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 8

ER -